Geron says its stem cell-based therapeutic product effective in treating mild spinal cord injury in rats

By Lisa Kerner

Charlotte, N.C., July 19 - Geron Corp. said preclinical animal studies demonstrated the safety of its lead human embryonic stem cell (hSEC)-based therapeutic product, GRNOPC1, for spinal cord injury.

In the studies, researchers injected GRNOPC1 into the lesion site of rats with very mild or moderate spinal cord contusion injuries. Results showed that GRNOPC1 survived in both the mild and moderate lesion sites.

Additionally, in the more severe injuries there was a broader distribution of transplanted cells and robust remyelination, similar to previous study results.

The studies were published in Regenerative Medicine.

Geron is a Menlo Park, Calif.-based biopharmaceutical company developing therapeutic products for the treatment of cancer and degenerative diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.